AstraZeneca has suffered from significant patent losses in recent years and has looked to asset sales as it refocuses. In its latest deal, the company sold certain rights to Vimovo and Nexium to Grünenthal. More: AstraZeneca gins up 5M in
read morePfizer acknowledged Tuesday that it continues to struggle with manufacturing at some Hospira plants, an issue that bodes ill not just for investors but also for U.S. hospitals. The manufacturing problems at Hospira that dented earnings and led it to
read moreAllergan CEO Brent Saunders brushes off suggestions that the company isn’t doing enough to drive growth—and his confidence got a bit of a boost with the company’s third-quarter results. But efforts to shed its women’s health and infectious disease units
read moreViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV. More: Encouraging data for ViiV’s long-acting, two-drug HIV therapy Source: News
read moreChancellor Philip Hammond has confirmed the planned funding boost for the NHS and announced an additional emergency cash injection for social services in his Autumn budget, but critics argue it will not be enough to weather the storm of increasing
read moreA new analysis by Diabetes UK has calculated that 500 people with diabetes die prematurely every week in England and Wales, with a significant number of these deaths down to avoidable complications. More: Diabetes causing 500 premature deaths a week
read more© 1994 - 2026 B.M. Pharmaceuticals